Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with informed consent, without presenting of any known contraindication for the use of Tranexamic acid and Tocilizumab.~Exclusion Criteria:~* patients or relatives who refused to consent, presenting of any known contraindication for the use of Tranexamic acid and Tocilizumab.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- SS-TG (Type: NO_INTERVENTION): Standard surgery using burr-hole procedure, irrigation and drainage.
- SS-TXA-TG (Type: ACTIVE_COMPARATOR): Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.
- SS-TXA-RoA (Type: ACTIVE_COMPARATOR): Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.

Based on this trial design, predict the completion outcome and termination type (if applicable).